Pharmacological prevention of breast cancer: Quo Vadis?

Research output: Contribution to journalArticle

Abstract

Although tamoxifen reduces breast cancer incidence by 30-40% in at-risk subjects, its adverse events may be a limiting factor. Thus, different strategies are being pursued to improve the risk:benefit ratio of breast cancer chemoprevention intervention. Firstly, raloxifene is being compared with tamoxifen in a phase-III trial, whereas the minimal active dose of tamoxifen is being assessed in phase I-II trials. The combination of HRT and tamoxifen may also reduce the risks while retaining the benefits of either agent. Anastrozole holds promise as a preventive agent based on preliminary data on contralateral breast cancer. Another important area is the appropriate identification of women at increased risk for ER-positive breast cancer due to reproductive factors, which may maximize the therapeutic index of hormonal agents. Finally, new targets that interfere with the onset of ER-negative breast cancer are being sought since one-third of breast cancers will not be modulated by hormonal interventions.

Original languageEnglish
Pages (from-to)379-386
Number of pages8
JournalBreast
Volume12
Issue number6
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Pharmacology
Tamoxifen
Breast Neoplasms
Chemoprevention
Odds Ratio
Incidence
Therapeutics

Keywords

  • Breast neoplasms
  • Chemoprevention
  • Clinical trial
  • Tamoxifen

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Pharmacological prevention of breast cancer : Quo Vadis? / Serrano, Davide; Bonanni, Bernardo; Cazzaniga, Massimiliano; Galli, Arianna; Gonzaga, Aliana Guerrieri; Decensi, Andrea.

In: Breast, Vol. 12, No. 6, 12.2003, p. 379-386.

Research output: Contribution to journalArticle

@article{562527577e8f429d9ce263d3d3594c1d,
title = "Pharmacological prevention of breast cancer: Quo Vadis?",
abstract = "Although tamoxifen reduces breast cancer incidence by 30-40{\%} in at-risk subjects, its adverse events may be a limiting factor. Thus, different strategies are being pursued to improve the risk:benefit ratio of breast cancer chemoprevention intervention. Firstly, raloxifene is being compared with tamoxifen in a phase-III trial, whereas the minimal active dose of tamoxifen is being assessed in phase I-II trials. The combination of HRT and tamoxifen may also reduce the risks while retaining the benefits of either agent. Anastrozole holds promise as a preventive agent based on preliminary data on contralateral breast cancer. Another important area is the appropriate identification of women at increased risk for ER-positive breast cancer due to reproductive factors, which may maximize the therapeutic index of hormonal agents. Finally, new targets that interfere with the onset of ER-negative breast cancer are being sought since one-third of breast cancers will not be modulated by hormonal interventions.",
keywords = "Breast neoplasms, Chemoprevention, Clinical trial, Tamoxifen",
author = "Davide Serrano and Bernardo Bonanni and Massimiliano Cazzaniga and Arianna Galli and Gonzaga, {Aliana Guerrieri} and Andrea Decensi",
year = "2003",
month = "12",
doi = "10.1016/S0960-9776(03)00140-1",
language = "English",
volume = "12",
pages = "379--386",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Pharmacological prevention of breast cancer

T2 - Quo Vadis?

AU - Serrano, Davide

AU - Bonanni, Bernardo

AU - Cazzaniga, Massimiliano

AU - Galli, Arianna

AU - Gonzaga, Aliana Guerrieri

AU - Decensi, Andrea

PY - 2003/12

Y1 - 2003/12

N2 - Although tamoxifen reduces breast cancer incidence by 30-40% in at-risk subjects, its adverse events may be a limiting factor. Thus, different strategies are being pursued to improve the risk:benefit ratio of breast cancer chemoprevention intervention. Firstly, raloxifene is being compared with tamoxifen in a phase-III trial, whereas the minimal active dose of tamoxifen is being assessed in phase I-II trials. The combination of HRT and tamoxifen may also reduce the risks while retaining the benefits of either agent. Anastrozole holds promise as a preventive agent based on preliminary data on contralateral breast cancer. Another important area is the appropriate identification of women at increased risk for ER-positive breast cancer due to reproductive factors, which may maximize the therapeutic index of hormonal agents. Finally, new targets that interfere with the onset of ER-negative breast cancer are being sought since one-third of breast cancers will not be modulated by hormonal interventions.

AB - Although tamoxifen reduces breast cancer incidence by 30-40% in at-risk subjects, its adverse events may be a limiting factor. Thus, different strategies are being pursued to improve the risk:benefit ratio of breast cancer chemoprevention intervention. Firstly, raloxifene is being compared with tamoxifen in a phase-III trial, whereas the minimal active dose of tamoxifen is being assessed in phase I-II trials. The combination of HRT and tamoxifen may also reduce the risks while retaining the benefits of either agent. Anastrozole holds promise as a preventive agent based on preliminary data on contralateral breast cancer. Another important area is the appropriate identification of women at increased risk for ER-positive breast cancer due to reproductive factors, which may maximize the therapeutic index of hormonal agents. Finally, new targets that interfere with the onset of ER-negative breast cancer are being sought since one-third of breast cancers will not be modulated by hormonal interventions.

KW - Breast neoplasms

KW - Chemoprevention

KW - Clinical trial

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0346888600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346888600&partnerID=8YFLogxK

U2 - 10.1016/S0960-9776(03)00140-1

DO - 10.1016/S0960-9776(03)00140-1

M3 - Article

C2 - 14659109

AN - SCOPUS:0346888600

VL - 12

SP - 379

EP - 386

JO - Breast

JF - Breast

SN - 0960-9776

IS - 6

ER -